Referenser Hypertoni

• Pearce KA, Furberg CD, Psaty BM, Kirk J. Cost-minimization and the number needed to treat in uncomplicated hypertension. Amer J Hypertensin ; 1998;11:618-29.
• Ramipril – njursvikt – ej diabetes
• Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in nondiabetic nephropathies with non-nephrotic proteinuria. Lancet 1999 Jul 31;354:359-64.
• Intensiv terapi – diabetes
• Gaede P, Vedel P, Parving H-H, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomized study. Lancet 1999 Feb 20;353:617-22.
• Äldre med systolisk hypertoni – diabetes resp icke diabetes
• Curb JD, Pressel SL, Cutler JA, et al., for the Systolic Hypertension in the Elderly Program Cooperative Research Group. Effect of diureticbased antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996 Dec 18;276:1886-92.
• HOPE
  The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med 2000 Jan 20;342:145-53.
• RENAAL
  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Eng J Med 2001;12:861-869.
• IDNT
  Renoprotective effect of the angiotensin-receptoragonist irbesartan with nephropathy due to type II diabetes. N Engl J Med 2001;345:851- 60.
• IRMA-2
  The effect of irbesartan on the development of diabetic nephropathy in patients with type II diabetes. N Eng J Med 2001;345:870-8.
• LIFE
  Dahlöf B, Devereux RB, Kjeldsen SE Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995–1003.
• ALLHAT
  Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997.
• ANBP2
  A comparison of Outcomes with Angiotensin-converting-Enzyme Inhibitors and Diuretics for Hypertension in the Elderly. The Second Australian National Blood Pressure Study Group (ANBP2). N Engl J Med 2003;348:583-592.
• SCOPE
  The study on cognition and prognosis (SCOPE): principal results of a randomized double-blind intervention trial. Journal of Hypertension 2003,21:875-886.
• SBU rapport nr 170/1, 2004: Måttligt förhöjt blodtryck www.sbu.se
• Metaanalys
  Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004;329:828831.
• VALUE
  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-2031.
• Lindholm LH, Carlberg B, Samuelsson O. Should ß blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-53.
• Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2008;366:895-906.
• ADVANCE
  Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-40.
• Nationella riktlinjer för hjärtsjukvård 2008 (socialstyrelsen.se). 
• ONTARGET
  Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events.The ONTARGET Investigators. N Engl J Med 2008;358:1547-59.
• TRANSCEND
  Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. The TRANSCEND Investigators. Lancet 2008;372:1174-83.
• HYVET
  Beckett NS et al. The HYVET Study Group. Treatment of Hypertension in Patients 80 Years of Age or Older. N Engl J Med 2008
• ACCOMPLISH
  Jamerson K,Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. New Engl J Med 2008;359:2417-28.
• Tandvårds- och läkemedelsförmånsverket. Genomgång av läkemedel mot högt blodtryck 2008. (tlv.se)
• SPRINT
  Research Group; Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control.N Engl J Med. 2015;373(22):2103-16.
• HOPE-3
  Yusuf S, et al. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. The New England Journal of Medicine. 2016. 374(21):2032-2343
• SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439-54.
• Visseren F, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-337.
• Hur mycket salt äter vi i Sverige? En uppskattning av befolkningens saltintag från befintliga data (livsmedelsverket.se)
• 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults https://www.ahajournals.org/doi/10.1161/HYP.0000000000000065